香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Laekna, Inc. 來凱醫藥有限公司 （於開曼群島註冊成立之有限公司） （股份代號：2105） 提名與企業管治委員會組成變動 來凱醫藥有限公司（「本公司」）董事（「董事」）會（「董事會」）宣佈，自二零二五年十 二月十二日起，執行董事謝玲女士和獨立非執行董事周健先生已獲委任為本公司 提名與企業管治委員會（「提名與企業管治委員會」）成員。於作出上述變動後，提 名與企業管治委員會包括五名成員，即呂向陽博士、尹旭東博士、利民博士、謝 玲女士和周健先生，呂向陽博士擔任提名與企業管治委員會主席。 上述變動乃為遵守香港聯合交易所有限公司證券上市規則附錄C1所載的經修訂企 業管治守則而作出。 承董事會命 來凱醫藥有限公司 主席 呂向陽博士 香港，2025年12月12日 於本公告日期，董事會包括執行董事呂向陽博士、謝玲女士及顧祥巨博士；非執 行董事王 ...

每经AI快讯，来凯医药-B(02105.HK)早盘涨超5%，截至发稿，涨5.63%，报16.9港元，成交额2869.72万 港元。 ...

Core Viewpoint - The stock of Lai Kai Pharmaceutical-B (02105) rose over 5% following the announcement of an exclusive agreement with Qilu Pharmaceutical for the research, development, and commercialization of LAE002 in China [1] Group 1: Company Developments - Lai Kai Pharmaceutical's stock increased by 5.63%, reaching HKD 16.9, with a trading volume of HKD 28.6972 million [1] - The company has signed an exclusive agreement with Qilu Pharmaceutical, allowing Qilu to conduct research and commercialization of LAE002 in China [1] - Lai Kai is responsible for completing the Phase III clinical trial for HR+/HER2- breast cancer until the first indication receives new drug application approval in China [1] Group 2: Financial Aspects - The agreement includes a non-refundable upfront payment of up to RMB 530 million and milestone payments related to clinical development [1] - The total potential upfront and milestone payments could reach RMB 2.045 billion, along with a sales revenue share of 10% to 20% from future net sales in the licensed region [1] Group 3: Pipeline Progress - According to Yongxing Securities, LAE002 is expected to submit its New Drug Application (NDA) in the first half of 2026 [1] - The company's pipeline is progressing well, with promising data for LAE102 and FDA approval for the IND application of LAE103 [1] - Yongxing Securities has initiated coverage of LAE102 using the DCF valuation method and has given the company a "buy" rating [1]

Core Viewpoint - The stock of Lai Kai Pharmaceutical-B (02105) rose over 5% following the announcement of an exclusive agreement with Qilu Pharmaceutical for the research, development, and commercialization of LAE002 in China [1] Group 1: Company Developments - Lai Kai Pharmaceutical has signed an exclusive agreement with Qilu Pharmaceutical, allowing Qilu to conduct research and commercialization of LAE002 in China [1] - The company is responsible for completing the Phase III clinical trial for HR+/HER2- breast cancer until the first indication receives new drug application approval in China [1] - Lai Kai Pharmaceutical is entitled to receive a non-refundable upfront payment of up to 530 million RMB and milestone payments for clinical development, with a potential total of 2.045 billion RMB in upfront and milestone payments [1] Group 2: Financial Projections - The company can earn a tiered sales revenue share of over 10% to 20% from future net sales in the licensed region [1] - Yongxing Securities forecasts that LAE002 is expected to submit a New Drug Application (NDA) in the first half of 2026 [1] - The company’s pipeline is progressing smoothly, with positive MAD data for LAE102 and FDA approval for the IND application of LAE103 [1] Group 3: Analyst Ratings - Yongxing Securities has initiated coverage on the company with a "Buy" rating, utilizing a DCF valuation method for LAE102 [1]

Core Viewpoint - The stock of Lai Kai Pharmaceutical-B (02105) rose over 5% following the announcement of an exclusive agreement with Qilu Pharmaceutical for the research, development, and commercialization of LAE002 in China [1] Group 1: Financial Details - Lai Kai Pharmaceutical is set to receive a non-refundable upfront payment of up to 530 million RMB and milestone payments related to clinical development [1] - The total potential upfront and milestone payments could reach up to 2.045 billion RMB, in addition to a tiered sales revenue share of over 10% to 20% from future net sales in the licensed region [1] Group 2: Clinical Development - The company is responsible for completing the Phase III clinical trial for HR+/HER2- breast cancer until the first indication receives new drug application approval in China [1] - According to Yongxing Securities, LAE002 is expected to submit its New Drug Application (NDA) in the first half of 2026 [1] Group 3: Pipeline Progress - The company’s pipeline is progressing smoothly, with promising data for LAE102 and FDA approval for the IND application of LAE103 [1] - Yongxing Securities has initiated coverage on LAE102 using the DCF valuation method and has given the company a "buy" rating [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | | | 致：香港交易及結算所有限公司 公司名稱: 來凱醫藥有限公司 呈交日期: 2025年12月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02105 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | | USD | | 0 | | 本月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | 本月底法定/註冊股本總額： USD 50,000 FF3 ...

每经AI快讯，来凯医药-B(02105.HK)涨超4%，截至发稿，涨4.92%，报17.27港元，成交额3214.93万港 元。 ...

Core Viewpoint - The announcement by Lai Kai Pharmaceutical-B (02105) regarding the licensing agreement for its breast cancer candidate drug LAE002 (afuresertib) to Qilu Pharmaceutical is a significant development in the domestic biopharmaceutical sector, with a total agreement value of up to 2.045 billion yuan [1] Group 1: Company Developments - Lai Kai Pharmaceutical's stock rose over 6%, currently trading at 17.27 HKD with a transaction volume of 32.1493 million HKD [1] - The licensing agreement includes an upfront payment and a revenue-sharing model where Lai Kai will receive 10%-20% of sales, ensuring funding for further research and development [1] Group 2: Product and Market Potential - LAE002 is a potent AKT inhibitor, with its global development progress second only to AstraZeneca's Capivasertib in the HR+/HER2- breast cancer indication [1] - The peak sales potential for LAE002 in the Chinese market is estimated to reach 2 billion yuan, while global sales could reference Capivasertib, which is projected to achieve 700-800 million USD in sales this year, with peak sales potentially exceeding 1-2 billion USD [1]

Core Viewpoint - LaiKai Pharmaceutical-B (02105) has seen a significant stock increase of over 6%, currently trading at 17.27 HKD, with a transaction volume of 32.15 million HKD, following the announcement of a major licensing deal for its breast cancer candidate drug LAE002 (afuresertib) in China [1] Group 1: Licensing Agreement - On November 12, LaiKai Pharmaceutical announced the licensing of its breast cancer candidate drug LAE002 to Qilu Pharmaceutical for a total agreement value of up to 2.045 billion RMB [1] - In addition to the upfront payment, LaiKai Pharmaceutical will receive a tiered revenue share of 10%-20% from sales, providing substantial funding for future research and development [1] - This transaction is noted as one of the larger licensing agreements in the domestic biopharmaceutical sector this year [1] Group 2: Drug Profile and Market Potential - LAE002 is a potent AKT inhibitor, with its global development progress second only to AstraZeneca's Capivasertib in the HR+/HER2- breast cancer indication [1] - Industry expectations suggest that LAE002 could achieve peak sales of 2 billion RMB in the Chinese market, while global performance may be benchmarked against Capivasertib, which is projected to generate sales of 700-800 million USD this year, with peak sales potentially exceeding 1-2 billion USD [1]

Group 1: Semiconductor Industry - Semiconductor stocks showed an upward trend, with Huahong Semiconductor rising 1.24% and SMIC increasing by 1.02%. The semiconductor industry is expected to continue its upward trajectory through 2025, driven by U.S. export controls and China's "14th Five-Year Plan" emphasizing technological self-reliance [1][2] Group 2: Pharmaceutical Sector - Lakai Pharmaceutical saw a significant increase of over 15%, with a cumulative rise of over 40% this month. The company has granted rights for its breast cancer candidate drug LAE002 to Qilu Pharmaceutical for a total transaction amount of 2.045 billion yuan, along with a potential sales commission of 10% to 20% [1] Group 3: Technology and AI - Cambridge Technology experienced a nearly 10% rise, with reports indicating that Meta is in talks with Google to potentially purchase TPUs for its data centers starting in 2027, with a procurement scale potentially reaching several billion dollars [1] - Guohua Tong surged over 14% after Huawei announced the launch of its first chat robot, "Smart Hanhan," priced at 399 yuan, marking Huawei's entry into the smart companionship market [2] - Xiaoma Zhixing reported a revenue increase of 72% year-on-year to 25.4 million USD in Q3 2025, with Robotaxi services growing by 89% [3] Group 4: Consumer Goods and Entertainment - Pop Mart rose over 8% after Sony Pictures acquired the film adaptation rights for Pop Mart's popular IP "Labubu," with plans for a movie series already in development [3] - Yuran Agriculture increased by over 9%, being recognized as the world's largest raw milk supplier with a comprehensive business model covering the entire dairy industry chain [4] Group 5: U.S. Market Movements - Robinhood's stock rose over 10.93% as the company announced the launch of a futures and derivatives exchange, deepening its investment in predictive markets [5] - Oracle's stock increased by 4.02% after Deutsche Bank raised its target price based on the company's growth potential in cloud infrastructure and AI services [6]